You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company plans to grow its business based on the FDA approval and preliminary national coverage determination for its FoundationOne CDx test last year.
A decade after their team at WashU sequenced the first tumor-normal genome pair, Mardis and Wilson are bringing cancer genomics to the clinic at Nationwide Children's Hospital.
Foundation Medicine will provide genomic profiling for the EORTC's Screening Patients for Efficient Clinical Trial Access program.
Among other projects, the company will make improvements to its internal bioinformatics pipeline and develop a 5,000-sample cohort for oncology research use.
The Danish informatics firm is exploring analytical tools for its InWeb_InBioMap network, which currently contains more than 700,000 protein-protein interactions.
The company beat analyst estimates on both the top and bottom line and reported a 50 percent year over year growth in clinical testing volume in Q3.
Investigators saw muted negative selection against mutations in genomic data for more than 7,600 tumors, while mining positive selection patterns for cancer driver clues.
The firm is currently marketing its deision support analysis directly to patients and doctors while working on pilot studies with genomics providers to potentially integrate its analysis into their own reports.
A life sciences industrial strategy out this week provided long-term guidance for supporting and enhancing growth in the sector in the UK.
Using blood samples from 200 cancer patients, researchers showed that it is possible to find most early cancer cases with targeted error correction sequencing.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.